Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV002486486 | SCV002791534 | uncertain significance | Hyperglycinuria; Neutral 1 amino acid transport defect; Iminoglycinuria | 2021-12-15 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001357408 | SCV001552875 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The SLC6A19 c.887+9G>A variant was not identified in the literature nor was it identified in the ClinVar, Cosmic or LOVD 3.0 databases. The variant was identified in dbSNP (ID: rs762018842) and in control databases in 4 of 280578 chromosomes at a frequency of 0.000014 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 3 of 24826 chromosomes (freq: 0.000121) and European (non-Finnish) in 1 of 127236 chromosomes (freq: 0.000008), but was not observed in the Latino, Ashkenazi Jewish, East Asian, European (Finnish), Other, and South Asian populations. The variant occurs outside of the splicing consensus sequence however 3 of 4 in silico or computational prediction software programs (MaxEntScan, NNSPLICE, and GeneSplicer) predict a greater than 10% difference in splicing and the creation of a new 5' splice site. However, this information is not predictive enough to assume pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |